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Abstract
Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine 
kinase (TAM RTK) family in diverse cancers. We investigated the prognostic relevance of GAS6 
expression, encoding the common TAM RTK ligand, in 270 adults (n=71 aged <60 years; n=199 
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aged ≥60 years) with de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients 
expressing GAS6 (GAS6+), especially those aged ≥60 years, more often failed to achieve a 
complete remission (CR). In all patients, GAS6+ patients had shorter disease-free (DFS) and 
overall (OS) survival than patients without GAS6 expression (GAS6−). After adjusting for other 
prognostic markers, GAS6+ predicted CR failure (P=0.02), shorter DFS (P=0.004) and OS 
(P=0.04). To gain further biologic insights, we derived a GAS6-associated gene-expression 
signature (P<0.001) that in GAS6+ patients included overexpressed BAALC and MN1, known to 
confer adverse prognosis in CN-AML, and overexpressed CXCL12, encoding stromal cell-derived 
factor, and its receptor genes, CXCR4 and CXCR7. This study reports for the first time that GAS6 
expression is an adverse prognostic marker in CN-AML. Although GAS6 decoy receptors are not 
yet available in the clinic for GAS6+ CN-AML therapy, potential alternative therapies targeting 
GAS6+-associated pathways, e.g., CXCR4 antagonists may be considered for GAS6+ patients to 
sensitize them to chemotherapy.
Keywords
GAS6; acute myeloid leukemia; prognosis
INTRODUCTION
Constitutive activity of the receptor tyrosine kinase (RTK) family has been observed in 
malignant blasts from patients with acute myeloid leukemia (AML). Members of the RTK 
family include FLT3 and KIT, whose constitutive kinase activity can occur through several 
mechanisms, such as mutationally-induced autophosphorylation, receptor overexpression 
and/or aberrant expression of the receptors’ ligands.1-3 The constitutive activity of FLT3 and 
KIT has been associated with poor clinical outcomes, and therapeutic targeting of activated 
RTKs is currently an area of intense investigation.4-8
In cancer, another RTK family, the TAM RTKs (i.e., TYRO3, AXL and MERTK), has been 
shown to support survival, proliferation, migration, invasion, angiogenesis, metastasis and 
chemoresistance,9-12 and TAM RTK inhibitors are already in pre-clinical and clinical 
development for several solid tumors.11-13 Although TAM RTKs are aberrantly expressed in 
AML,11,14,15 to date, only AXL expression has been reported to adversely impact outcome in 
adults with cytogenetically normal AML (CN-AML).16
No AXL mutations have been described in AML, suggesting activation of AXL may occur at 
least in part via aberrant autocrine expression of GAS6, that binds AXL with high affinity 
and is also the common ligand for all three TAM RTKs.17 GAS6 was shown to be aberrantly 
expressed in AML cell lines.18 These data point to a possible role for the GAS6/TAM RTK 
signaling axis in AML and prompted us to test the clinical impact of GAS6 expression in a 
molecularly characterized cohort of chemotherapy-treated adults with de novo CN-AML.
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METHODS
Patients
Available pretreatment bone marrow or blood samples were obtained from 270 patients with 
de novo CN-AML (aged 18 to 83 years; median, 66 years; n=71 aged <60 years; n=199 aged 
≥60 years) enrolled on Cancer and Leukemia Group B (CALGB)/Alliance companion 
protocols 8461 (cytogenetic analyses), 20202 (molecular analyses) and 9665 (tissue 
banking). Patients were treated on CALGB/Alliance protocols 8525, 8923, 9420, 9720, 
10201, or 19808.19-25 The treatment protocols included cytarabine/daunorubicin-based 
induction but differed with regard to consolidation therapy (for details see Supplemental 
Material). Per protocols, no patient received allogeneic stem-cell transplantation in first 
complete remission (CR). All protocols were in accordance with the Declaration of Helsinki 
and approved by institutional review boards at each center, and all patients provided written 
informed consent.
Cytogenetic and molecular analyses
For the patient’s karyotype to be considered normal, ≥20 metaphases from short-term 
cultures of the bone marrow specimens obtained at diagnosis had to have been analyzed and 
the normal result confirmed by central karyotype review.26 Tissue samples were 
cryopreserved after mononuclear cell enrichment through a Ficoll gradient. The presence or 
absence of FLT3 internal tandem duplication (FLT3-ITD),27 FLT3 tyrosine kinase domain 
mutations (FLT3-TKD),28 MLL partial tandem duplication (MLL-PTD),29,30 mutations in 
the NPM1,31 CEBPA,32 WT1,33 TET2,34 IDH1/2,35 RUNX1,36 ASXL136 and DNMT3A37 
genes, and BAALC,38 ERG,38 and MN139 expression levels were assessed centrally as 
previously described. Patients were also categorized according to the European 
LeukemiaNet (ELN) reporting system.40 CN-AML patients with CEBPA mutation and/or 
NPM1 mutation without FLT3-ITD were classified in a Favorable genetic group and those 
with wild-type CEBPA, FLT3-ITD and/or NPM1 mutation, or wild-type NPM1 in an 
Intermediate-I genetic group
Expression analysis of GAS6 and TAM RTKs
GAS6, TYRO3, AXL and MERTK transcript expression levels measured with Affymetrix 
U133 plus 2.0 array (Affymetrix, Santa Clara, CA, USA) assays. The GeneAnnot chip 
definition file was used to derive a single expression value for each gene per patient 
sample.41 For array normalization and expression value computation, the robust multichip 
average method was implemented separately for samples from older and younger patients.42
Patients were categorized as either expressing GAS6 (yes or GAS6-positive, hereafter 
denoted GAS6+) if the probe-set fluorescence intensity (PFI) was greater than background 
fluorescence intensity (BFI) and not expressing GAS6 (no or GAS6-negative denoted 
GAS6−) if the GAS6 PFI was less than or equal to the BFI. Similarly, patients were 
categorized as either TYRO3+ or AXL+ (if the PFIs were greater than BFI) and TYRO3− or 
AXL− (if the PFIs were less than or equal to BFI). The MERTK PFI was above the BFI in all 
samples and, based on an optimal cutpoint analysis (see Supplemental Material),43 patients 
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were grouped into high expressers (MERTK+) or lower expressers (MERTK−) if they were 
in the upper two tertiles or in the lowest tertile groups, respectively.
Affymetrix-microarray gene expression profiling analysis
To establish a signature of genes differentially expressed between GAS6+ and GAS6− 
patients, we evaluated the aforementioned Affymetrix gene-expression profiles. Normalized 
expression values were compared between GAS6+ and GAS6− patients and a univariable 
significance level of P<0.001 was used to identify differentially expressed genes. A global 
test of significance based on a permutation procedure was performed to determine whether 
or not the number of differentially expressed genes was more than expected by chance. The 
false discovery rate (FDR) was used to assess multiple testing errors. A permutation test was 
computed based on 1 000 random permutations.
The Ingenuity Pathway Analysis tool (IPA Tool; Ingenuity H Systems, Redwood City, CA, 
USA; http://www.ingenuity.com) was used to identify enriched biological networks, global 
functions and functional pathways. Genes with altered expression profile associated with 
GAS6 expression status were imported into the IPA Tool. As a second means for identifying 
enriched ontologies, the web-based Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) tool (DAVID Bioinformatics resources 6.7 http://
david.abcc.ncifcrf.gov/) was used.
Clinical endpoints and statistical analyses
Baseline characteristics were compared between GAS6+ and GAS6− patients using the 
Fisher’s exact test for categorical variables and the Wilcoxon rank-sum test for continuous 
variables. Definitions of clinical endpoints [i.e., CR, disease-free (DFS) and overall (OS) 
survival] and details of outcome analyses are provided in the Supplemental Material. 
Briefly, for time-to-event analyses, we calculated survival estimates using the Kaplan-
Meier44 method, and compared groups by the log-rank test. We constructed age group-
adjusted multivariable logistic regression models to analyze factors associated with the 
achievement of CR, and age group-adjusted multivariable Cox proportional hazards 
models45 for factors associated with survival endpoints. All analyses were performed by the 
Alliance for Clinical Trials in Oncology Statistics and Data Center.
RESULTS
Association of GAS6 expression status with clinical characteristics, TAM RTK expression 
status and molecular markers at diagnosis
Of the 270 patients, 26% of patients were GAS6+, (n=69) and 74% GAS6− (n=201). At 
diagnosis, GAS6+ patients had higher platelet counts (P=0.03), lower percentages of blood 
blasts (P=0.01), more often hepatomegaly (P=0.006) and co-expression of AXL (28% vs 5%, 
P<0.001) compared with GAS6− patients. There was no association between GAS6 and 
TYRO3 expression (P=0.74), whereas more GAS6− than GAS6+ patients were MERTK+ 
(P=0.02, Table 1). Compared with GAS6− patients, GAS6+ patients were more often wild-
type for NPM1 (P<0.001) and CEBPA (P=0.02) and therefore more often in the ELN 
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Intermediate-I Genetic Group (P<.001), and had mutations in RUNX1 (P<0.001) and ASXL1 
(P=0.002), and high BAALC (P=0.02) and MN1 (P=0.05; Table 1) expression.
Impact of GAS6 expression on clinical outcomes of de novo CN-AML patients
In age group-adjusted analyses, GAS6+ expression associated with lower odds of achieving 
CR (P<0.001; Table 2), with CR rates significantly different in patients ≥60 years of age 
[46% GAS6+ (n=54) vs 74% GAS6− (n=145); P<0.001]. None of the TAM RTKs impacted 
on CR (Table S1). To assess whether GAS6 expression independently affects clinical 
outcomes when other known clinical and molecular prognostic features are considered, we 
performed multivariable analyses (MVAs). For CR, GAS6+ status predicted lower 
probability of achieving CR [(P=0.02; odds ratio (OR), 0.46; 95% confidence interval (CI), 
0.23-0.89)], after adjusting for the ELN CN-AML Genetic Group45 status, BAALC 
expression status, white blood cell (WBC) count and age group (Table 3).
GAS6+ expression associated with shorter DFS (P=0.03) and OS (P=0.004) compared with 
GAS6− patients (Table 2 and Figure 1). As single markers, neither AXL nor MERTK 
influenced DFS or OS, whereas TYRO3 expression adversely impacted on both endpoints 
(Table S1). In multivariable modeling for DFS and OS, we noted a significant interaction 
(DFS, P=0.01; OS, P=0.04) between GAS6 expression and the combined TYRO3 and AXL 
expression status. In the dual receptor-positive patients, i.e., positive for one or both TYRO3 
and AXL expression, GAS6 expression did not independently impact outcome, which may be 
reflective of the interplay between the GAS6 ligand and the TYRO3 and AXL receptors 
(Table 3). In the dual receptor-negative patients, i.e., negative for both TYRO3 and AXL 
expression, GAS6 expression remained an independent, adverse prognostic marker. Within 
the subgroup of dual receptor-negative patients, GAS6+ expression was a predictor of 
shorter DFS (P=0.004; hazard ratio (HR)=2.12; 95% CI, 1.27-3.56) and after adjusting for 
WT1 and DNMT3A R882 mutations, BAALC expression and age group; and shorter OS 
(P=0.04; HR=1.55; 95% CI, 1.01-2.38) after adjusting for ELN group, WT1 and DNMT3A 
R882 mutations, BAALC expression, WBC and age group.
A GAS6-associated gene expression signature in de novo CN-AML
To gain additional molecular insights into GAS6+ CN-AML, an Affymetrix microarray-
based gene expression signature was derived. The signature contained 1 238 genes that were 
significantly differentially expressed between GAS6+ and GAS6− CN-AML blasts at 
diagnosis (Table S2). Within this signature, genes for which high expression level is an 
established adverse prognosticator in CN-AML were BAALC and MN1. These were 
overexpressed, respectively, 2.57-fold and 2.41-fold in the GAS6+ subgroup. Although 
hitherto not validated in large, independent patient sets, overexpression of the following four 
genes was reported to have an impact on outcome of AML patients. These were APP, which 
encodes the amyloid precursor protein and whose overexpression was associated with 
shorter survival than that of AML patients without APP overexpression46 (overexpressed 
3.37-fold in GAS6+ patients); SETBP1, whose overexpression leads to PP2A inhibition, 
promoting proliferation of leukemic cells47 (overexpressed 1.73-fold); SPARC, which is 
overexpressed in patients with IDH2-R172 mutations and contributes to AML 
aggressiveness48 (overexpressed 2.05-fold); and CD74, whose lower surface protein levels 
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associated with achievement of CR/partial CR in AML patients ages 60-75 years treated 
with bortezomib in combination with chemotherapy (overexpressed 2.51-fold).49 Moreover, 
overexpressed in GAS6+ CN-AML diagnostic samples were CXCL12 (3.2-fold), encoding 
for stromal cell-derived factor-1, and genes encoding both of its receptors, CXCR4 (1.52-
fold) and CXCR7 (1.72-fold). Overexpression of CXCR4 has been previously associated 
with adverse clinical outcome in patients with CN-AML.50,51
CEBPA was among the 611 genes underexpressed in GAS6+ patients. Mutations in the 
CEBPA gene that encodes a transcription factor are associated with better outcome of AML 
patients (Table S2).32 CD33, encoding an immunotherapeutic target in AML, was also 
underexpressed (1.67-fold) in GAS6+ patients.
Gene expression signatures were not identified for any of the TAM RTKs (less than 10 
genes, with FDRs of 10%; data not shown). Indeed, there was no apparent contribution from 
TAM RTKs in profiling analyses combining GAS6 with each of the TAM RTKs. This 
indicates that it is GAS6 expression status that drives the differential gene expression we 
observed.
Pathway analysis revealed that the GAS6-associated gene expression signature contained the 
following overrepresented molecular and cellular functions: a) cell cycle, b) cellular growth 
and proliferation, c) cell death and survival, d) cellular assembly and organization and, e) 
DNA replication, recombination and repair (Table 4). The top canonical pathways included 
a) IL-8 signaling, b) growth hormone signaling, c) mitotic roles of Polo-like kinase, d) 
CXCR4 signaling and e) Tec kinase signaling (Table 4). Of the top upstream regulators, 
colony stimulating factor 2 (granulocyte-macrophage), CSF2, was predicted by Ingenuity to 
be activated, while the cyclin dependent kinase inhibitor, CDKN1A, was predicted by 
Ingenuity to be inhibited (Table 4). A second analysis using DAVID also identified enriched 
clusters of genes, with the most highly enriched cluster (score of 9.66; Benjamini corrected 
P-values ranging from 2.8E-9 to 3.5E-6) containing genes involved in the cell cycle (data 
not shown).
DISCUSSION
We report herein that GAS6 expressed by AML blasts is a marker of poor clinical outcomes 
in adults with CN-AML, independent of other established prognostic markers in this 
cytogenetic subset. Not only does GAS6 expression predict CR failure, albeit driven by older 
age, it has also a negative impact on DFS and OS in the studied cohort. The MVA revealed 
the negative prognostic impact of GAS6 was in patients whose leukemic blasts did not 
express TYRO3 and AXL. This suggests that GAS6 may contribute to a more aggressive 
disease through signaling mechanisms that are not dependent on AXL and TYRO3 expression 
within the AML cells. Perhaps it is the third GAS6 receptor, MERTK that together with 
GAS6 has a role within the TYRO3−/AXL− patient subgroup. Based on recently published 
data related to MERTK function in leukemia, MERTK, even when expressed at relatively 
low levels appears to contribute to a leukemic phenotype. 14 However, in the current study, 
too few numbers of patients prohibited a reliable GAS6/MERTK subgroup analyses.
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Given that GAS6 expression has an adverse impact on CR achievement, mainly in older 
patients, and on DFS and OS in all patients, this warrants development of novel, less toxic 
and perhaps more personalized therapies targeting GAS6. We recently reported that 
blocking the engagement of GAS6 to the AXL receptor with soluble AXL-Fc chimeric 
protein inhibits downstream signal transduction, inducing differentiation and apoptosis in 
human AML cell lines and patient samples with activated AXL.54 Consistent with our 
work,54 a recent study by Ben-Batalla et al,55 showed that pharmacologic inhibition of 
GAS6/AXL signaling induces leukemic cell death. We did not find an impact of AXL-
positive expression as a sole marker on outcomes in our study, whereas AXL expression 
above the median was associated with shorter OS in the Ben-Batalla and colleagues study.55 
This may be explained in part by therapy differences and differences in patient cohort 
characteristics. Their study exclusively analyzed adult patients ≤60 years of age, whereas 
73% of patients in our study were 60 years of age or older.
As our study measured GAS6 transcript levels, the relationship between GAS6 mRNA, 
protein and secretion in AML is not yet clear. However, there are several studies of various 
solid cancers that report GAS6 mRNA and protein are present within the tumor cells. For 
example, Buehler and coworkers recently reported that GAS6 mRNA and the translated 
protein are both elevated within ovarian cancer.56 Additionally, GAS6 mRNA and protein 
levels were found in 81% and 74% of glioblastoma multiforme tissue samples, suggesting a 
close 1:1 relationship between transcription and translation of GAS6.57 As for secretion, 
Ben-Batalla, and co-workers performed immunohistochemistry for GAS6 on five AML 
patients’ bone marrows and concluded that stromal cells are the primary source of secreted 
GAS6 ligand (their Figure 1 and Supplement Table 3)55
Interaction of the GAS6/TAM RTK signaling axis with the stromal microenvironment in 
solid tumors has been associated with poor progression-free survival,58,59 A similar 
mechanism may be active in chemotherapy-resistant AML patients that express GAS6. This 
suggests a potential for novel therapies targeting GAS6+ leukemic blasts that could also 
simultaneously inhibit negative effects of GAS6 in the microenvironment, ultimately 
improving patient survival. Promising studies using decoy receptors showed significant 
activity against the growth of lung carcinoma cells in a xenograft model,13 and the absence 
of toxicity in normal murine tissues or hematopoiesis is encouraging.60 Given our current 
findings, GAS6-targeted therapeutic agents could lead to higher CR rates, particularly, as 
our data indicate, benefiting older patients, and possibly prolonging survival of the GAS6+ 
subset of CN-AML patients. Furthermore, while our results await independent validation, 
development of GAS6 decoy receptors, in addition to selective small molecule TAM 
inhibitors, appears warranted.
Meanwhile, in the short term, one possibility for improving outcomes of GAS6+ patients is 
alluded to by the GAS6-associated gene expression signature we identified. Overexpression 
of CXCR4 and its ligand was detected in pretreatment samples from patients expressing 
GAS6. In separate reports, overexpression of this signaling axis associated with increased 
risk of relapse and shorter overall survival in AML.50,51 CXCR4 is expressed on normal 
hematopoietic stem cells and regulates stem cell homing and retention in the BM when 
CXCL12, produced by BM stroma, engages the receptor.61 The CXCR4 antagonist, 
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Plerixafor, currently has FDA approval in combination with G-CSF as a stem cell 
mobilizing agent for patients with multiple myeloma and non-Hodgkin lymphoma who 
undergo autologous hematopoietic stem cell transplantation.62 Uy and co-workers63 recently 
reported their results of a phase I/II clinical trial that demonstrated antagonizing the 
CXCL12/CXCR4 axis with Plerixafor induces chemosensitization of relapsed or refractory 
AML blasts. Thus, although GAS6 decoy receptors are not yet available in the clinic for 
GAS6+ CN-AML therapy, potential alternative therapies such as CXCR4 antagonists should 
be considered for GAS6+ patients to sensitize them to chemotherapy.
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Figure 1. 
Clinical outcome by GAS6 expression status. Survival curves for (a) disease-free survival 
(DFS) and (b) overall survival (OS) are displayed for GAS6+ and GAS6− patient groups. 
Data were age adjusted (<60 years of age, n=71; ≥60 years of age, n=199).
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Table 1
Comparison of clinical and molecular characteristics of de novo cytogenetically normal AML patients 
according to GAS6 expression status
Variable GAS6+a(n=69)
GAS6−a
(n=201) P
b
Age, years 0.02
 Median 68 65
 Range 37-81 18-83
Age group, n (%) 0.35
 <60 years 15 (22) 56 (28)
 ≥60 years 54 (78) 145 (72)
Male sex, n (%) 35 (51) 101 (50) 1.00
Race, n (%) 0.81
 White 63 (93) 181 (91)
 Non-white 5 (7) 19 (9)
Hemoglobin, g/dL 0.56
 Median 9.4 9.4
 Range 6.4-12.5 4.8-15.0
Platelet count, ×109/L
 Median 84 66
 Range 11-309 4-850
White blood cell count, ×109/L
 Median 21.1 26.5
 Range 1.0-434.1 1.0-450.0
Blood blasts (%) 0.01
 Median 40 59
 Range 0-96 0-99
Bone marrow blasts (%) 0.87
 Median 70 67
 Range 7-97 4-97
Extramedullary involvement, n (%) 20 (29) 45 (23) 0.33
 Hepatomegaly 8 (12) 5 (3) 0.006
TYRO3 expression group a , n (%) 0.74
 Positive 16 (23) 43 (21)
 Negative 53 (77) 158 (79)
AXL expression group a , n (%) <0.001
Leukemia. Author manuscript; available in PMC 2014 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Whitman et al. Page 15
Variable GAS6+a(n=69)
GAS6−a
(n=201) P
b
 Positive 19 (28) 11 (5)
 Negative 50 (72) 190 (95)
MERTK expression c, n (%) 0.02
 Positive 38 (55) 143 (71)
 Negative 31 (45) 58 (29)
TYRO3/AXL dual receptor d , n (%) 30 (43) 51 (25) 0.006
NPM1, n (%) <0.001
 Mutated 20 (29) 141 (70)
 Wild-type 48 (71) 60 (30)
FLT3-ITD, n (%) 0.56
 Present 26 (38) 68 (34)
 Absent 42 (62) 133 (66)
CEBPA, n (%) 0.02
 Mutated 4 (6) 35 (17)
  Single mutated 4 19
  Double mutated 0 16
 Wild-type 64 (94) 166 (83)
ELN Genetic Group e , n (%) <0.001
 Favorable 12 (18) 115 (57)
 Intermediate-I 56 (82) 86 (43)
FLT3-TKD, n (%) 1.00
 Present 7 (10) 23 (11)
 Absent 61 (90) 178 (89)
WT1, n (%) 0.25
 Mutated 2 (3) 15 (7)
 Wild-type 66 (97) 186 (93)
TET2, n (%) 0.43
 Mutated 15 (22) 55 (28)
 Wild-type 52 (78) 143 (72)
MLL-PTD, n (%) 1.00
 Present 4 (6) 13 (7)
 Absent 64 (94) 182 (93)
IDH1, n (%) 0.83
 R132 5 (7) 24 (12)
 V71I 2 (3) 0 (0)
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Variable GAS6+a(n=69)
GAS6−a
(n=201) P
b
 Wild-type 60 (90) 173 (88)
IDH2, n (%) 0.72
  IDH2 14 (21) 37 (19)
  R140 8 33
  R172 6 4
 Wild-type 53 (79) 160 (81)
RUNX1, n (%) <0.001
 Mutated 27 (44) 9 (5)
 Wild-type 35 (56) 173 (95)
ASXL1, n (%) 0.002
 Mutated 16 (24) 16 (8)
 Wild-type 51 (76) 179 (92)
DNMT3A, n (%) 0.76
 Mutated 21 (32) 66 (35)
  R882 17 40
  Non-R882 4 26
 Wild-type 44 (68) 124 (65)
ERG expression group f , n (%) 0.33
 High 30 (43) 102 (51)
 Low 39 (57) 99 (49)
BAALC expression group f , n (%) 0.02
 High 44 (64) 93 (46)
 Low 25 (36) 108 (54)
MN1 expression group f , n (%) 0.05
 High 34 (65) 65 (48)
 Low 18 (35) 70 (52)
Abbreviations: FLT3-ITD, internal tandem duplication of the FLT3 gene; ELN, European LeukemiaNet; FLT3-TKD, tyrosine kinase domain 
mutation in the FLT3 gene; MLL-PTD, partial tandem duplication of the MLL gene.
aAll patients with GAS6 probe-set fluorescence intensity greater than the background fluorescence intensity (BFI) are defined as GAS6-positive 
(GAS6+) and those with GAS6 probe-set intensity less than or equal to the BFI as GAS6-negative (GAS6−). Similarly, patients were categorized as 
either TYRO3+ (TYRO3 expression greater than BFI) or TYRO3− (if TYRO3 expression was less than or equal to BFI) and AXL+ (expression 
greater than BFI) or AXL− (expression less than or equal to BFI).
b
P-values for categorical variables are from Fisher’s exact test, P-values for continuous variables are from Wilcoxon rank sum test.
cAll patients in the upper 2/3 of the values of MERTK are defined as MERTK+. All patients in the lower 1/3 of the values of MERTK are defined as 
MERTK−.
d
If patient has AXL+ and TYRO3+ expression, AXL+ and TYRO3− expression, or AXL− and TYRO3+ expression then TYRO3/AXL dual receptor is 
defined to be positive. If a patient has AXL− and TYRO3− expression then TYRO3/AXL dual receptor is defined to be negative.
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eAccording to the ELN recommendations,40 Favorable Genetic Group is defined as CEBPA-mutated or FLT3-ITD-negative and NPM1-mutated. 
Intermediate-I Genetic Group is defined as CEBPA wild-type and FLT3-ITD-positive and NPM1-mutated, FLT3-ITD-negative and NPM1-wild-
type, or FLT3-ITD-positive and NPM1-wild-type.
f
The median expression value was used as the cutoff for high and low values.
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Table 2
Age group-adjusted analyses of outcomes by GAS6 positive expression versus no expression in de novo 
cytogenetically normal AML patients
Outcome Endpoint OR/HR (95% CI) P
CR 0.35 (0.20, 0.63) <0.001
DFS 1.55 (1.05, 2.26) 0.03
OS 1.55 (1.16, 2.09) 0.004
Abbreviations: CR, complete remission; DFS, disease-free survival; OS, overall survival; OR, odds ratio; HR, hazard ratio; CI, confidence interval.
Note: ORs < 1.0 means a lower CR rate, and HRs > 1.0 mean higher risk
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Table 4
Biological pathways over-represented in the GAS6 expression signature in cytogenetically normal AML
Molecular and cellular functions (number of genes) a P b
Cell cycle (202) 7.75E-17 to 2.15E-03a
Cellular growth and proliferation (360) 3.48E-15 to 2.41E-03
Cell death and survival (363) 5.28E-15 to 2.44E-03
Cellular assembly and organization (195) 2.76E-11 to 2.33E-03
DNA replication, recombination and repair (136) 2.76E-11 to 2.15E-03
Top canonical pathways a
Interleukin-8 signaling 5.43E-06
Growth hormone signaling 2.28E-05
Mitotic roles of Polo-like kinase 7.24E-05
CXCR4 signaling 1.23E-04
Tec kinase signaling 1.62E-04
Top upstream regulators a
Colony stimulating factor 2 (granulocyte-macrophage), CSF2 9.17E-16
Cyclin-dependent kinase inhibitor, CDKN1A 2.55E-15
a
These data were obtained from Ingenuity’s Pathway Analysis program (see Methods)
bSignificance values shown indicate the range of P-values for each of the genes that were identified within each of the annotated functions listed
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